The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | NICHE-3 of nivolumab and relatlimab in dMMR colon cancer compared to NICHE-2
Myriam Chalabi, MD, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the results of the NICHE-2 (NCT03026140) and NICHE-3 (NCT03026140) trials, which evaluate immunotherapy in MMR-deficient (dMMR) colon cancer. In NICHE-2, the findings suggest circulating tumor DNA (ctDNA) may guide organ preservation strategies in the future. NICHE-3, using a different immunotherapy combination (nivolumab and relatlimab), demonstrated similar results. Safety profiles were comparable, though NICHE-3 had a slightly higher rate of mild endocrine-related side effects. Both trials underscore the strong response of MMR-deficient colon cancer patients to short-term immunotherapy before surgery. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
